Congenica, a digital health company specializing in genomic data analysis, is partnering with myTomorrows to accelerate access to precision oncology for cancer patients globally. This collaboration aims to provide physicians with opportunities to access pre-approval anti-cancer treatments and clinical trials, especially for patients who can’t be treated with approved options. The program, launching in Q1 2024, will enable physicians to refer patients through Congenica’s Precision Oncology solution to myTomorrows’ platform for trial search and enrollment requests.
What You Should Know:
– Congenica, a digital health company specializing in the provision of software and solutions for genomic data analysis and interpretation, and myTomorrows, a global platform facilitating access to pre-approval treatments and clinical trials, have partnered to expedite access to precision oncology for cancer patients worldwide.
– The strategic partnership between Congenica and myTomorrows will open new opportunities for physicians to search for access to pre-approval anti-cancer treatments and active clinical trials, specifically for patients whose cancers cannot be treated with approved treatment options.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
– The program is set to launch in the first quarter of 2024 and will enable physicians to refer patients via Congenica’s Precision Oncology solution to the myTomorrows platform where they can search for applicable trials and request enrollment.
Source: Hit Consultant